Igniting the Future of Healthcare: Spark Biomedical Secures $15M Series A to Transform Neurostimulation

Spark Biomedical Inc is proud to announce that we have successfully raised $15,000,000 in funding, marking a pivotal milestone in our journey to revolutionize healthcare through non-invasive neurostimulation solutions. Founded in Dallas in 2018, our company has quickly become a beacon of innovation and compassion. Our breakthrough began with the Sparrow Therapy System—a first-generation, FDA-cleared, drug-free treatment designed to alleviate opioid withdrawal symptoms. Today, with our second-generation device, Sparrow Ascent, we are expanding our mission to bend the curve on opioid addiction and tackle diverse health challenges with even greater impact. This substantial funding injection will accelerate our research and development efforts, enabling us to refine our cutting-edge neurostimulation technology further and extend its applications to a broader range of conditions. Our vision is underpinned by our commitment to equip healthcare providers and researchers with evidence-based, innovative tools that redefine treatment protocols while maintaining an unwavering focus on patient wellbeing. The resources raised will also drive our plans to expand our operational footprint, support clinical trials, and fortify our manufacturing capabilities to meet the growing demand for safer, more effective treatment alternatives. At Spark Biomedical, we believe in the power of bold ideas, agility in execution, and a collaborative spirit that pushes boundaries in science and patient care. Our mission is not only to innovate but to transform lives through accessible, state-of-the-art neurostimulation solutions. With this new funding, we are more equipped than ever to expand our reach, inspire further breakthroughs, and ultimately change the world of healthcare for the better.